Lobucavir is phosphorylated in human cytomegalovirus-infected and - uninfected cells and inhibits the viral DNA polymerase

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 12, 1997, Pages 2680-2685

  Tenney, D J ^a   Yamanaka, G ^a   Voss, S M ^a   Cianci, C W ^a   Tuomari, A V ^a   Sheaffer, A K ^a   Alam, M ^a   Colonno, R J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; GANCICLOVIR; LOBUCAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS INFECTION; DNA SYNTHESIS INHIBITION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMEDIATE EARLY GENE; INHIBITION KINETICS; PHOSPHORYLATION; PRIORITY JOURNAL; SKIN FIBROBLAST; VIRUS ISOLATION;

EID: 0030734329     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.12.2680     Document Type: Article

References (58)

1. Biron, K. K. 1996. Cytomegalovirus: genetics of drug resistance. Adv. Exp. Med. Biol. 394:135-143.
2. Biron, K. K., J. A. Fyfe, S. C. Stanat, L. K. Leslie, J. B. Sorrell, C. U. Lambe, and D. M. Coen. 1986. A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl) ethoxy] methyl) guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc. Natl. Acad. Sci. USA 83:8769-8773.
3. Biron, K. K., S. C. Stanat, J. B. Sorrell, J. A. Fyfe, P. M. Keller, C. U. Lambe, and D. J. Nelson. 1985. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 82:2473-2477.
4. Braitman, A., M. R. Swerdel, S. J. Olsen, A. V. Tuomari, J. S. Lynch, B. Blue, T. Michalik, A. K. Field, D. P. Bonner, and J. M. Clark. 1991. Evaluation of SQ 34,514: Pharmacokinetics and efficacy in experimental herpesvirus infections in mice. Antimicrob. Agents Chemother. 35:1464-1468.
5. Chee, M. S., A. T. Bankier, S. Beck, R. Bohni, C. M. Brown, R. Cerny, T. Horsnell, C. A. Hutchison III, T. Kouzarides, J. A. Martignetti, E. Preddie, S. C. Satchwell, P. Tomlinson, K. M. Weston, and B. G. Barrell. 1990. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr. Top. Microbiol. Immunol. 154:125-169.
6. Chee, M. S., G. L. Lawrence, and B. G. Barrell. 1989. Alpha-, beta- and gammaherpesviruses encode a putative phosphotransferase. J. Gen. Virol. 70:1151-1160.
7. Chou, S., A. Erice, M. C. Jordan, G. M. Vercellotti, K. R. Michels, C. L. Talarico, S. C. Stanat, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:576-583.
8. Clement, J. J., and E. R. Kern. 1991. Cyclobutyl compounds as antiviral agents. Transplant. Proc. 23(Suppl. 3):159-161.
9. Crumpacker, C. S. 1996. Drug therapy: ganciclovir. N. Engl. J. Med. 335:721-729.
10. Depto, A. S., and R. M. Stenberg. 1989. Regulated expression of the human cytomegalovirus pp65 gene: octamer sequence in the promoter is required for activation by viral gene products. J. Virol. 63:1232-1238.
11. Elion, G. B., P. A. Furman, J. A. Fyfe, P. DeMiranda, L. Beauchamp, and H. J. Schaeffer. 1977. Proc. Natl. Acad. Sci. USA 74:5716-5720.
12. Erice, A., S. Chou, K. K. Biron, S. C. Stanat, H. H. Balfour, and M. C. Jordan. 1989. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 320:289-293.
13. Field, A. K., A. V. Tuomari, B. McGeever-Rubin, B. J. Terry, K. E. Mazina, M. L. Haffey, M. E. Hagen, J. M. Clark, A. Braitman, W. A. Slusarchyk, M. G. Young, and R. Zahler. 1990. (+)-(1α,2b,3a)-9-[2,3-Bis (hydroxymethyl) cyclobutyl] guanine [(±)BHCG]: a potent and selective inhibitor of herpesviruses. Antivir. Res. 13:41-52.
14. Freitas, V. R., D. F. Smee, M. Chernow, R. Boehme, and T. R. Matthews. 1985. Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses. Antimicrob. Agents Chemother. 28:240-245.
15. Fyfe, J. A. 1982. Differential phosphorylation of (E)-5-(2-bromovinyl)-2′-deoxyuridine monophosphate by thymidine kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus. Mol. Pharmacol. 21:432-437.
16. Hamatake, R. K. Unpublished data.
17. Hayashi, S., D. W. Norbeck, W. Rosenbrook, R. L. Fine, M. Matsukura, J. J. Plattner, S. Broder, and H. Mitsuya. 1990. Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro. Antimicrob. Agents Chemother. 34:287-294.
18. He, Z., Y. S. He, Y. Kim, L. Chu, C. Ohmstede, K. K. Biron, and D. M. Coen. 1997. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J. Virol. 71:405-411.
19. Hung, L.-F., A. E. Brumbaugh, G. Bhatia, P. L. Marion, P. P. Hung, D. W. Norbeck, J. J. Plattner, and W. S. Robinson. 1991. Effects of purine nucleoside analogues with a cyclobutane ring and erythromycin A oxime derivatives on duck hepatitis B virus replication in vivo and in cell culture and HIV-1 in cell culture. J. Med. Virol. 35:180-186.
20. Innaimo, S. F., M. Seifer, G. S. Bisacchi, D. N. Standring, R. Zahler, and R. J. Colonno. 1997. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrobial Agents Chemother. 41:1444-1448.
21. Izuta, S., N. Shimada, M. Kitagawa, M. Suzuki, K. Kojima, and S. Yoshida. 1992. Inhibitory effects of triphosphate derivatives of oxetanocin G and related compounds on eukaryotic and viral DNA polymerases and human immunodeficiency virus reverse transcriptases. J. Biochem. 112:81-87.
22. Kohlbrenner, W. E., C. D. Carter, S. W. Fesik, D. W. Norbeck, and J. Erikson. 1990. Efficiency of phosphorylation of the Cyclobut-G (A-69992) enantiomers by HSV-1 thymidine kinase does not correlate with their antiherpesvirus activity. Biochem. Pharmacol. 40:R5-R10.
23. Kouzarides, T., A. T. Bankier, A. C. Satchwell, K. Weston, P. Tomlinson, and B. G. Barrell. 1987. Large scale rearrangement of homologous regions in the genomes of HCMV and EBV. Virology 157:397-413.
24. Koyano, S., T. Suzutani, I. Yoshida, and M. Azuma. 1996. Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes. Antimicrob. Agents Chemother. 40:920-923.
25. Littler, E., A. D. Stuart, and M. S. Chee. 1992. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358:160-162.
26. Lurain, N. S., L. E. Spafford, and K. D. Thompson. 1994. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J. Virol. 68:4427-4431.
27. Lurain, N. S., K. D. Thompson, E. W. Holmes, and G. S. Read. 1992. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J. Virol. 66:7146-7152.
28. Mar, E. C., Y. C. Cheng, and E.-S. Huang. 1983. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 24:518-521.
29. Mar, E.-C., J.-F. Chiou, Y.-C. Cheng, and E.-S. Huang. 1985. Inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J. Virol. 53:776-780.
30. Martin, J. C., C. A. Dvorak, D. F. Smee, T. R. Matthews, and J. P. H. Verheyden. 1983. 9-[1,3-dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. J. Med. Chem. 26:759-761.
31. Martinez, J., R. S. Lahijani, and S. C. St. Jeor. 1989. Analysis of a region of the human cytomegalovirus (AD169) genome coding for a 25-kilodalton virion protein. J. Virol. 63:233-241.
32. Maruyama, T., Y. Sato, T. Horii, H. Shiota, K. Nitta, T. Shirasaka, H. Mitsuya, and M. Honjo. 1990. Synthesis and antiviral activities of carbocyclic oxetanocin analogues. Chem. Pharm. Bull. (Tokyo) 38:2719-2725.
33. Maruyama, T., Y. Hanai, Y. Sato, R. Snoeck, G. Andrei, M. Hosoya, J. Balzarini, and E. De Clercq. 1993. Synthesis and antiviral activities of carbocyclic oxetanocin analogues (c-oxt-A, c-oxt-G) and related compounds. Chem. Pharm. Bull. (Tokyo) 41:516-521.
34. Metzger, C., D. Michel, K. Schneider, A. Luske, H. J. Schlicht, and T. Mertens. 1994. Human cytomegalovirus UL97 kinase confers ganciclovir susceptibility to recombinant vaccinia virus. J. Virol. 68:8423-8427.
35. Michel, D., I. Pavic, A. Zimmermann, E. Haupt, K. Wunderlich, M. Heuschmid, and T. Mertens. 1996. The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J. Virol. 70:6340-6346.
36. Nishiyama, Y. N., N. Yamamoto, Y. Yamada, T. Daikoku, Y. I. Ichikawa, and K. Takahashi. 1989. Anti-herpesvirus activity of carbocyclic oxetanocin G in vitro. J. Antibiot. (Tokyo) 42:1854-1859.
37. Norbeck, D. W., E. Kern, S. Hayashi, W. Rosenbrook, H. Sham, J. Herrin, R. Swanson, N. Shipkowitz, D. Hardy, K. Marsh, G. Arnett, W. Shannon, S. Broder, and H. Mitsuya. 1990. Cyclobut-A and cyclobut-G: broad-spectrum antiviral agents with potential utility for the therapy of AIDS. J. Med. Chem. 33:1281-1285.
38. Peppel, K., and C. Baglioni. 1990. A simple and fast method to extract RNA from tissue culture cells. BioTechniques 9:710-713.
39. Rasmussen L., J. Mullenax, R. Nelson, and T. C. Merigan. 1985. Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. J. Virol. 55:274-280.
40. Rawlinson, W. D., H. E. Farrell, and B. G. Barrell. 1996. Analysis of the complete DNA sequence of murine cytomegalovirus. J. Virol. 70:8833-8849.
41. Rudolph, S.-A., T. Stamminger, and G. Jahn. 1990. Transcriptional analysis of the eight-kilobase mRNA encoding the major capsid protein of human cytomegalovirus. J. Virol 64:5167-5172.
42. Sheaffer, A. K., S. P. Weinheimer, and D. J. Tenney. J. Gen. Virol., in press.
43. Slusarchchyk, W. A., M. G. Young, G. S. Bisacchi, D. R. Hockstein, and R. Zahler. 1989. Synthesis of SQ-33,054, a novel cyclobutane nucleoside with potent antiviral activity. Tetrahedron Lett. 30:6453-6456.
44. Smee, D. F., B. B. Barnett, R. W. Sidwell, E. J. Reist, and A. Holy. 1995. Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus. Antivir. Res. 26:1-9.
45. Smith, R. F., and T. F. Smith. 1989. Identification of new protein kinase-related genes in three herpesviruses, herpes simplex virus, varicella-zoster virus, and Epstein-Barr virus. J. Virol. 63:450-455.
46. Stanat, S. C., J. E. Reardon, A. Erice, M. C. Jordan, W. L. Drew, and K. K. Biron. 1991. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob. Agents Chemother. 35:2191-2197.
47. Stenberg, R. M., A. S. Depto, J. Fortney, and J. A. Nelson. 1989. Regulated expression of early and late RNAs and proteins from the human cytomegalovirus immediate early gene region. J. Virol. 63:2699-2708.
48. Sullivan, V., C. L. Talarico, S. C. Stanat, M. Davis, D. M. Coen, and K. K. Biron. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162-164.
49. Sullivan, V., K. K. Biron, C. Talarico, S. C. Stanat, M. Davis, L. M. Pozzi, and D. M. Coen. 1993. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob. Agents Chemother. 37:19-25.
50. Tenney, D. J., and A. M. Colberg-Poley. 1991. Human cytomegalovirus immediate-early RNA: temporally regulated expression of nuclear, cytoplasmic, and polysome-associated transcripts during infection. J. Virol. 65:6724-6734.
51. Tenney, D. J., and A. M. Colberg-Poley. 1991. Expression of the human cytomegalovirus UL36-38 immediate early region during permissive infection. Virology 182:199-210.
52. Tenney, D. J., P. A. Micheletti, J. T. Stevens, R. K. Hamatake, J. T. Matthews, A. R. Sanchez, W. W. Hurlburt, M. Bifano, and M. G. Cordingley. 1993. Mutations in the C terminus of herpes simplex virus type 1 DNA polymerase can affect binding and stimulation by its accessory protein UL42 without affecting basal polymerase activity. J. Virol. 67:543-547.
53. Terry, B. J., C. W. Cianci, and M. E. Hagen. 1991. Inhibition of herpes simplex virus type 1 DNA polymerase by [1R(1α,2β,3α)]-9-[2,3-Bis(hydroxymethyl) cyclobutyl]guanine. Mol. Pharmacol. 40:591-596.
54. Wahren, B., A. Larsson, U. Ruden, A. Sundqvist, and E. Solver. 1987. Acyclic guanosine analogs as inhibitors of human cytomegalovirus. Antimicrob. Agents Chemother. 31:317-320.
55. Yamanaka, G., A. V. Tuomari, M. Cristodoulides, and A. K. Field. 1991. (R)-BHCA, (SQ-34,990): a dihydroxymethylcyclobutyl deoxyadenosine analog active against ganciclovir-resistant HCMV, p. 341-344. In M. P. Landini (ed.), Excerpta medica international congress series, Third International Cytomegalovirus Workshop. Elsevier Science Publishers, Amsterdam, The Netherlands.
56. Yamanaka, G., A. V. Tuomari, M. Hagen, B. McGeever-Rubin, B. J. Terry, M. Haffey, G. S. Bisacchi, and A. K. Field. 1991. Selective activity and cellular pharmacology of (1R-1α,2β,3α)-9-[2,3-bis(hydroxymethyl)cyclobutyl] guanine in herpesvirus infected cells. Mol. Pharmacol. 40:446-453.
57. Yamanaka, G. Unpublished observations.
58. Yang, H., R. L. Drain, C. A. Franco, and J. M. Clark. 1996. Efficacy of BMS-180194 against experimental cytomegalovirus infections in immunocompromised mice. Antivir. Res. 29:233-241.